• AstraZeneca’s Datroway won a positive CHMP opinion for EU approval in first-line metastatic triple-negative breast cancer patients ineligible for PD-1/PD-L1 inhibitors.
• Recommendation was based on Phase III TROPION-Breast02, showing median overall survival of 23.7 months vs 18.7 months on chemotherapy.
• Datroway is jointly developed with Daiichi Sankyo; the drug is already approved in the US for the same setting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AstraZeneca plc published the original content used to generate this news brief on June 26, 2026, and is solely responsible for the information contained therein.